IgG4-related pharyngitis-an addition to the nomenclature of IgG4-related disease: comment on the article by Stone et al.
G. Fatemi,M. Fang
DOI: https://doi.org/10.1002/art.37999
2013-08-01
Arthritis & Rheumatism
Abstract:To the Editor: We read with great interest the article by Stone et al on recommendations for the nomenclature of individual organ manifestations of IgG4-related disease (1), and we suggest adding IgG4-related pharyngitis to the list of manifestations. To our knowledge, biopsy-proven IgG4-related disease involving the pharynx has rarely been described (2,3). We recently evaluated a patient who presented with dysphagia, and the assessment revealed IgG4-related disease involving the pharynx. The patient, a 60-year-old man with a medical history of type 2 diabetes mellitus, hyperlipidemia, and hypertension, presented with dysphagia that had progressed over several months. His symptoms began with difficulty swallowing solids but progressed over a 4-month period to difficulty swallowing liquids (which led to a 40-pound weight loss). Results of initial laboratory tests were significant for a hemoglobin level of 8.4 gm/dl (normal 13.3–17.7) and elevated erythrocyte sedimentation rate of 122 mm/hour (normal 0–20). Findings of flexible endoscopy revealed significant fullness of the right lateral pharyngeal wall, without distinct exophytic masses. Computed tomography scan of the neck showed an infiltrating mass extending from the right lateral pharyngeal tonsillar pillar to the level of the right true vocal cord. Loss of normal fat planes was seen, with extension of the process into the right parapharyngeal and paralaryngeal fat with no separation between the right medial pterygoid and right prevertebral musculature. The patient subsequently underwent an open-neck biopsy of the mass, and initial pathologic examination revealed marked acute and chronic inflammation without malignancy. The Armed Forces Institute of Pathology was consulted for a second opinion. Examination of the tissue revealed a sclerosing fibroinflammatory process extending into fibroadipose tissue, skeletal muscle, and nerves. Scattered lymphoid aggregates with conspicuous plasma cells and eosinophils were also noted. Plasma cells were immunoreactive with IgG, with significant concentrations of IgG4 (Figure 1). These features were most consistent with IgG4-related disease. Serum IgG4 levels were elevated at 163 mg/dl (normal 4–86). Following the diagnosis of IgG4-related pharyngitis, the patient was treated with a tapering course of prednisone followed by 2 courses of rituximab (1,000-mg dose each), with modest improvement in the dysphagia. To our knowledge, biopsy proven IgG4-related disease involving the pharynx has rarely been reported in the literature in the context of multiorgan involvement. Masterson et al described the case of a 58-year-old woman who presented with a right parapharyngeal mass near the tonsil (2). Over the course of 7 years, she developed multiple masses in other organs including the gallbladder, lungs, pelvis, omentum, eyes, and left temporal bone. She was initially diagnosed as having metastatic inflammatory myofibroblastic tumor, but the diagnosis was changed to IgG4-related disease several years later following retrospective pathologic review of all organs involved (2). Fujita et al reported on the manifestations of IgG4-related disease involving the mediastinum that extended to a submucosal mass-like lesion of the larynx, as seen on computed tomography and magnetic resonance imaging (3). Our case represents the first description of IgG4-related disease isolated in the pharynx. We propose adding IgG4-related pharyngitis to the preferred nomenclature of individual organ manifestations of IgG4-related disease. Using unified criteria for the nomenclature of IgG4-related disease will facilitate our understanding of its pathogenesis, natural history, and treatment.